641 related articles for article (PubMed ID: 21803855)
1. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
2. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
Herman SE; Johnson AJ
Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
[TBL] [Abstract][Full Text] [Related]
5. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
7. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.
Macias-Perez IM; Flinn IW
Curr Hematol Malig Rep; 2013 Mar; 8(1):22-7. PubMed ID: 23114654
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Burger JA
Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
[TBL] [Abstract][Full Text] [Related]
9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
11. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Han TT; Fan L; Li JY; Xu W
Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
[TBL] [Abstract][Full Text] [Related]
12. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
Vanhaesebroeck B; Khwaja A
Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
14. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
Davids MS; Deng J; Wiestner A; Lannutti BJ; Wang L; Wu CJ; Wilson WH; Brown JR; Letai A
Blood; 2012 Oct; 120(17):3501-9. PubMed ID: 22955911
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
16. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
17. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
20. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M; Hennessy BT; Knight ZA; Henneberg M; Hu J; Kurtova AV; Wierda WG; Keating MJ; Shokat KM; Burger JA
Blood; 2009 May; 113(22):5549-57. PubMed ID: 19318683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]